Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013128 · ClinicalTrials.gov registry record · Phase 1
Ublituximab + Ibrutinib in Select B-cell Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 18
- Study locations
NCT02013128: Completed Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by TG Therapeutics.
NCT02013128 is a Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma that has completed, run by TG Therapeutics. The registered enrollment target is 66 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (64% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02013128, a Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
Primary Outcome
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
Conditions Studied
Interventions
- DRUG Ublituximab
- DRUG Ibrutinib
Study Locations (18)
Texas
- TG Therapeutics Investigational Trial Site - Austin
- TG Therapeutics Investigational Trial Site - Dallas
- TG Therapeutics Investigational Trial Site - Tyler
Illinois
- TG Therapeutics Investigational Trial Site - Niles
- TG Therapeutics Investigational Trial Site - Urbana
Oregon
- TG Therapeutics Investigational Trial Site - Portland
- TG Therapeutics Investigational Trial Site - Springfield
Virginia
- TG Therapeutics Investigational Trial Site - Blacksburg
- TG Therapeutics Investigational Trial Site - Fairfax
Alabama
- TG Therapeutics Investigational Trial Site - Huntsville
Arizona
- TG Therapeutics Investigational Trial Site - Tucson
California
- TG Therapeutics Investigational Trial Site - Santa Barbara
Colorado
- TG Therapeutics Investigational Trial Site - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-01-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT02013128 record still lists
NCT02013128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Ublituximab is the first listed.
NCT02013128 lists 18 locations in 13 states (Texas, Illinois, Oregon).
Frequently Asked Questions
What is clinical trial NCT02013128 about?
NCT02013128 is a clinical study titled "Ublituximab + Ibrutinib in Select B-cell Malignancies". The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
What is the current status of trial NCT02013128?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2014-01-06. Estimated completion is 2015-12.
What conditions does trial NCT02013128 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma.
What interventions are being tested in trial NCT02013128?
The interventions under investigation include: Ublituximab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02013128?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02013128 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02013128's enrollment target sits among peer trials
66 82nd of 187 higher than 106 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI